CRACKLE: Carbapenems in Klebsiella pneumoniae and Other Enterobacteriaceae

CRACKLE: Carbapenems in Klebsiella pneumoniae and Other Enterobacteriaceae

You are here

The Consortium on Resistance Against Carbapenems in Klebsiella and other Enterobacteriaceae (CRACKLE) is a federally funded, prospective multi-center consortium to track carbapenem-resistant Enterobacteriacea. As part of this program strains and associated clinical data are being collected to investigate the association of various carbapenem-resistant Klebsiella pneumoniae (CRKp) clades with clinical and genomic features. The Antibiotic Resistance Leadership Group (ARLG) has contributed additional funding to obtain minimum inhibitory concentration (MIC) data and very limited molecular characterization for CRACKLE strains.

The overarching hypothesis of the CRACKLE program is that certain CRKP clades belonging to the ST258 sequence type carry specific genes that impact clinical outcomes and that these genetic elements are non-uniformly distributed among ST258 strains. Genome sequencing and analysis under this supplement will augment the existing CRACKLE and ARLG funded study of CRACKLE strains.

Funding

This project has been funded in whole or part with federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services under Award Number U19AI110819.